Britain and America have concluded a key trade agreement that will guarantee no import taxes on UK pharmaceutical products being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to increase expenditure on medicines through the public health system. This move secures that import taxes on these crucial goods will be held at zero for a period of the next three years.
This deal comes after previous warnings to significantly raise duties on branded pharmaceutical products, with figures mentioned up to double the cost.
"This agreement with the United Kingdom strengthens the worldwide climate for innovative medicines and brings long-overdue balance to transatlantic drug exports," an announcement said.
Commercial Impact
Drugs constitute one of the the United Kingdom's biggest goods shipped to the US, which is by far the largest destination for leading companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months prior to the third quarter, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This value represented 17.4% of total UK exports in that timeframe.
"This deal secures jobs, stimulates investment and paves the way for the UK to establish itself as a international leader for medical research," a government official commented.
Key UK Commitments
The deal includes several key commitments from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a aim to double overall NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage manufacturers must refund to the NHS to stay within budget will be limited at 15%. In the past, repayments topped twenty percent.
Recent Tensions
This agreement takes place against a long-running dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
These tensions were intensified by assertions that American patients were paying significantly more for the same drugs than people in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while major investments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS had to increase expenditure on medicines, noting that its spending on drugs had shrunk as a proportion of its total funding over the last ten years.
